Duncker Streett & Co’s AstraZeneca AZN Stock Holding History

Duncker Streett & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-33	Closed	-$4.4K	–	492
2023 Q3	$4.4K	Hold	33	–	–	﹤0.01%	438
2023 Q2	$4.65K	Hold	33	–	–	﹤0.01%	437
2023 Q1	$4.51K	Hold	33	–	–	﹤0.01%	427
2022 Q4	$4.41K	Hold	33	–	–	﹤0.01%	444
2022 Q3	$4K	Hold	33	–	–	﹤0.01%	424
2022 Q2	$4K	Hold	33	–	–	﹤0.01%	435
2022 Q1	$4K	Hold	33	–	–	﹤0.01%	440
2021 Q4	$4K	Hold	33	–	–	﹤0.01%	469
2021 Q3	$4K	Hold	33	–	–	﹤0.01%	469
2021 Q2	$4K	Hold	33	–	–	﹤0.01%	468
2021 Q1	$3K	Hold	33	–	–	﹤0.01%	471
2020 Q4	$3K	Hold	33	–	–	﹤0.01%	481
2020 Q3	$4K	Buy	+33	New	+$3.67K	﹤0.01%	462
2017 Q3	–	Sell	-577	Closed	-$39K	–	600
2017 Q2	$39K	Hold	577	–	–	0.01%	406
2017 Q1	$36K	Hold	577	–	–	0.01%	425
2016 Q4	$31K	Hold	577	–	–	0.01%	431
2016 Q3	$38K	Buy	+577	New	+$37.7K	0.01%	389

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Duncker Streett & Co's AZN Position: Q4 2023 in Review

Duncker Streett & Co sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 33 shares — an estimated $4.4K sold.

Duncker Streett & Co first reported a position in AZN in Q3 2016 and held it in 17 quarters. The position peaked at $39K in Q2 2017. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

Duncker Streett & Co reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
Duncker Streett & Co sold 33 AstraZeneca shares in Q4 2023, an estimated $4.4K.
Duncker Streett & Co first reported a position in AstraZeneca in Q3 2016 and held it in 17 quarters.
Duncker Streett & Co's AstraZeneca position peaked at $39K in Q2 2017.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Duncker Streett & Co's 13F filing for Q4 2023, filed 30 Jan 2024.